On the floor.

1. What is Saberry, and what made amla worth studying more closely?
2. What does standardizing for β-glucogallin add?
3. What have the human studies taught you so far?
4. Where do you see the most promising applications for Saberry?
5. What does a formulator need to consider when putting it into a finished product?
6. What research or product innovation are you most excited about next?

Short clips: Is all amla basically the same? What can’t I tell from “amla” on a label? What’s the gap between a promising ingredient study and a finished product?

Sent to Shaheen Oct 23; feedback pending. Avoid drug-comparison claims.

1. Why is perimenopause an important opportunity in women’s wellness?
2. What is happening in the body during this stage, and what do people commonly misunderstand?
3. What role does the liver play in hormone metabolism?
4. What is D-glucarate, and how does CelluThrive fit into this story?
5. What evidence can we point to today, and what questions still need research?
6. What could supplement brands do better for this consumer?

Condensed on-site version; revised questions were emailed Oct 28. Brian’s feedback and approved public claims are pending. Do not use the unpublished 56% figure without support and approval.

Hold questions until Jay confirms the featured topic and sends research/approved claims. Prep prompts:

1. What problem brought BlueRoot to this ingredient or product?
2. What is the one thing practitioners should understand about it?
3. What evidence supports that story, and what remains to be studied?
4. How could it show up in a consumer product people actually use?

Not sent or approved. Topic, assets, Jay’s mobile, and floor meeting point still pending.

Amy · SAMe

1. For someone hearing about SAMe for the first time, what is it, and what does it do naturally in the body?
2. Why has SAMe attracted interest from practitioners, and what does the scientific evidence tell us today?
3. What makes SAMe unusually difficult to formulate and keep stable?
4. If two products both list “SAMe 400 mg,” why might the actual amount available differ?
5. What formulation and packaging decisions protect stability and potency?
6. What should a practitioner look for when evaluating a SAMe supplement?

Dan · quality

1. What prompted NOW to test multiple SAMe products in the marketplace?
2. What does failed potency mean in practice?
3. Why is SAMe particularly vulnerable?
4. How does NOW check that its own product meets its label claim through shelf life?
5. What can practitioners and consumers look for if they can’t run a lab test themselves?

Revised version sent Oct 28; Amy/Dan approval pending. Confirm Amy’s participation and time.

Hold questions until NURA selects its featured ingredient/product. Prep prompts:

1. What is the product or ingredient, and why did NURA choose to focus on it?
2. What should practitioners know about how it works?
3. Which study or result best explains why it matters?
4. What does it make possible for finished consumer products?

Not sent or approved. Confirm speaker roles, claims, assets, and booth filming plan.